IL300586A - SARM1 inhibitors - Google Patents
SARM1 inhibitorsInfo
- Publication number
- IL300586A IL300586A IL300586A IL30058623A IL300586A IL 300586 A IL300586 A IL 300586A IL 300586 A IL300586 A IL 300586A IL 30058623 A IL30058623 A IL 30058623A IL 300586 A IL300586 A IL 300586A
- Authority
- IL
- Israel
- Prior art keywords
- ring
- nitrogen
- compound
- compound according
- sulfur
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069408P | 2020-08-24 | 2020-08-24 | |
| US202163142398P | 2021-01-27 | 2021-01-27 | |
| PCT/US2021/047093 WO2022046606A1 (en) | 2020-08-24 | 2021-08-23 | Inhibitors of sarm1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL300586A true IL300586A (en) | 2023-04-01 |
Family
ID=77775005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL300586A IL300586A (en) | 2020-08-24 | 2021-08-23 | SARM1 inhibitors |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12043613B2 (OSRAM) |
| EP (1) | EP4200293A1 (OSRAM) |
| JP (2) | JP7349046B2 (OSRAM) |
| KR (1) | KR20230057396A (OSRAM) |
| AU (2) | AU2021333558C1 (OSRAM) |
| BR (1) | BR112023002575A2 (OSRAM) |
| CA (1) | CA3189181A1 (OSRAM) |
| CL (1) | CL2023000525A1 (OSRAM) |
| CO (1) | CO2023001975A2 (OSRAM) |
| CR (1) | CR20230113A (OSRAM) |
| DO (1) | DOP2023000038A (OSRAM) |
| EC (1) | ECSP23012981A (OSRAM) |
| IL (1) | IL300586A (OSRAM) |
| MX (1) | MX2023002256A (OSRAM) |
| PE (1) | PE20230737A1 (OSRAM) |
| TW (2) | TWI786777B (OSRAM) |
| WO (1) | WO2022046606A1 (OSRAM) |
| ZA (1) | ZA202301801B (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12083114B2 (en) | 2018-12-19 | 2024-09-10 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 in combination with neuro-protective agents |
| US12404265B2 (en) | 2020-08-04 | 2025-09-02 | Nura Bio, Inc. | Substituted pyridine derivatives as SARM1 inhibitors |
| US11945796B2 (en) | 2020-09-16 | 2024-04-02 | Nura Bio, Inc. | Substituted pyridine derivatives as SARM1 inhibitors |
| AU2022320699A1 (en) | 2021-07-28 | 2024-02-29 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
| EP4558148A2 (en) * | 2022-07-21 | 2025-05-28 | Amylyx Pharmaceuticals Inc. | Oligonucleotide compositions and methods thereof |
| CN120457107A (zh) * | 2022-12-15 | 2025-08-08 | 维泰瑞隆有限公司 | Sarm1调节剂、其制备和用途 |
| WO2024158775A1 (en) | 2023-01-24 | 2024-08-02 | Disarm Therapeutics, Inc. | Pyridazines as sarm1 inhibitors |
| WO2024222835A1 (en) * | 2023-04-27 | 2024-10-31 | Sironax Ltd. | Sarm1 modulators, preparations, and uses thereof |
| CN119219603A (zh) * | 2023-06-28 | 2024-12-31 | 科辉智药(深圳)新药研究中心有限公司 | Sarm1酶活性抑制剂及其用途 |
| WO2025045746A1 (en) * | 2023-08-25 | 2025-03-06 | F. Hoffmann-La Roche Ag | Pyrazole derivatives as sarm1 inhibitors useful for the treatment of neurodegenerative disorders |
| WO2025049184A1 (en) | 2023-08-25 | 2025-03-06 | Eli Lilly And Company | (s)-3-((6-fluoropyridin-3-yl)methyl)-1-(5-(pyridin-4-yl)-4h-1,2,4-triazol-3-yl)piperidin-2-one benzenesulfonate |
| WO2025076017A1 (en) * | 2023-10-05 | 2025-04-10 | Genentech, Inc. | Carbamates for use as sarm1 inhibitors |
| WO2025076088A1 (en) * | 2023-10-05 | 2025-04-10 | Genentech, Inc. | Lactams for use as sarm1 inhibitors |
| WO2025157895A1 (en) | 2024-01-25 | 2025-07-31 | UCB Biopharma SRL | Pyrrolidinone derivatives |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2302417A1 (en) | 1997-10-27 | 1999-05-06 | Takeda Chemical Industries, Ltd. | Adenosine a3 receptor antagonists |
| US6787555B2 (en) | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| CA2504320A1 (en) | 2002-10-30 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| EP1581222A2 (en) | 2003-01-02 | 2005-10-05 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-&bgr; |
| TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| ATE464303T1 (de) | 2004-04-28 | 2010-04-15 | Vertex Pharma | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen |
| RU2423351C2 (ru) | 2004-12-16 | 2011-07-10 | Вертекс Фармасьютикалз Инкорпорейтед | Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний |
| CA2656159C (en) | 2006-06-28 | 2014-12-16 | Aska Pharmaceutical Co., Ltd. | Pyridylisoxazole derivatives |
| BRPI0717097A2 (pt) | 2006-09-21 | 2013-11-26 | Novartis Ag | Derivados de pirrol úteis para o tratamento de doenças mediadas por citocina |
| US8940771B2 (en) | 2007-12-20 | 2015-01-27 | Novartis Ag | Organic compounds |
| WO2009080705A2 (en) | 2007-12-20 | 2009-07-02 | Novartis Ag | Bis-thiazole derivatives, process for their preparation and their use as medicaments |
| TW201004941A (en) | 2008-07-16 | 2010-02-01 | Wyeth Corp | Alpha7 nicotinic acetylcholine receptor inhibitors |
| WO2010093849A2 (en) | 2009-02-13 | 2010-08-19 | Amgen Inc. | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions |
| US20120328629A1 (en) | 2011-06-24 | 2012-12-27 | University Of Miami | Therapeutic Applications Targeting SARM1 |
| EP2914591B1 (en) | 2012-11-03 | 2017-10-11 | Boehringer Ingelheim International GmbH | Inhibitors of cytomegalovirus |
| WO2014099694A1 (en) | 2012-12-19 | 2014-06-26 | Merck Sharp & Dohme Corp. | FACTOR IXa INHIBITORS |
| RU2570907C2 (ru) | 2013-10-21 | 2015-12-20 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа. |
| WO2015084936A1 (en) | 2013-12-04 | 2015-06-11 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
| US11357800B2 (en) | 2016-08-16 | 2022-06-14 | Henry Ford Health System | Compositions for the treatment of neuropathic pain and sensitization of tumors to chemotherapies |
| JP7044789B2 (ja) | 2016-09-24 | 2022-03-30 | ワシントン・ユニバーシティ | Ｓａｒｍ１ ｎａｄアーゼ活性の阻害剤およびその使用 |
| UY37512A (es) | 2016-12-09 | 2019-04-30 | Vertex Pharma | Compuestos pirazol 1,3-sustituido útiles para la reducción de los niveles de ácidos grasos de cadena muy larga |
| CN110337436A (zh) * | 2016-12-22 | 2019-10-15 | 拜耳作物科学股份公司 | 取代的1,2,4-噻二唑基吡咯酮和1,2,4-噻二唑基乙内酰脲及其盐及其作为除草剂的用途 |
| WO2018114663A1 (de) | 2016-12-22 | 2018-06-28 | Bayer Cropscience Aktiengesellschaft | Substituierte azolylpyrrolone und azolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| AU2018388406B2 (en) | 2017-12-22 | 2023-07-06 | HiberCell Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| WO2019236890A1 (en) * | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| JP2021527125A (ja) | 2018-06-07 | 2021-10-11 | ディサーム・セラピューティクス・インコーポレイテッドＤｉｓａｒｍ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｓａｒｍ１阻害剤 |
| JP7478142B2 (ja) | 2018-06-07 | 2024-05-02 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１阻害剤 |
| US12084436B2 (en) | 2019-01-30 | 2024-09-10 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP7289375B2 (ja) | 2019-06-06 | 2023-06-09 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１の阻害剤 |
| US20220340546A1 (en) | 2019-06-14 | 2022-10-27 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| MX2022000950A (es) | 2019-07-22 | 2022-02-14 | Bayer Ag | 5-amino pirazoles y triazoles como plaguicidas. |
| EP4028013A4 (en) | 2019-09-12 | 2023-10-18 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS |
| AU2020380395A1 (en) | 2019-11-05 | 2022-05-26 | Dermira, Inc. | MrgprX2 antagonists for the treatment of inflammatory disorders |
| KR20220164471A (ko) | 2020-01-07 | 2022-12-13 | 디스암 테라퓨틱스, 인크. | Sarm1의 억제제 |
| JP7477642B2 (ja) | 2020-04-09 | 2024-05-01 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１の阻害剤 |
| ES3049432T3 (en) | 2020-04-09 | 2025-12-16 | Disarm Therapeutics Inc | Indazole derivatives as inhibitors of sarm1 |
| US12404265B2 (en) | 2020-08-04 | 2025-09-02 | Nura Bio, Inc. | Substituted pyridine derivatives as SARM1 inhibitors |
-
2021
- 2021-08-20 TW TW110130799A patent/TWI786777B/zh active
- 2021-08-20 TW TW111144632A patent/TW202334117A/zh unknown
- 2021-08-23 BR BR112023002575A patent/BR112023002575A2/pt unknown
- 2021-08-23 CR CR20230113A patent/CR20230113A/es unknown
- 2021-08-23 MX MX2023002256A patent/MX2023002256A/es unknown
- 2021-08-23 US US17/408,956 patent/US12043613B2/en active Active
- 2021-08-23 PE PE2023000530A patent/PE20230737A1/es unknown
- 2021-08-23 KR KR1020237009643A patent/KR20230057396A/ko active Pending
- 2021-08-23 EP EP21770372.7A patent/EP4200293A1/en active Pending
- 2021-08-23 IL IL300586A patent/IL300586A/en unknown
- 2021-08-23 JP JP2023513172A patent/JP7349046B2/ja active Active
- 2021-08-23 WO PCT/US2021/047093 patent/WO2022046606A1/en not_active Ceased
- 2021-08-23 CA CA3189181A patent/CA3189181A1/en active Pending
- 2021-08-23 AU AU2021333558A patent/AU2021333558C1/en active Active
-
2023
- 2023-02-14 ZA ZA2023/01801A patent/ZA202301801B/en unknown
- 2023-02-22 CL CL2023000525A patent/CL2023000525A1/es unknown
- 2023-02-22 CO CONC2023/0001975A patent/CO2023001975A2/es unknown
- 2023-02-23 EC ECSENADI202312981A patent/ECSP23012981A/es unknown
- 2023-02-23 DO DO2023000038A patent/DOP2023000038A/es unknown
- 2023-09-08 JP JP2023145779A patent/JP7756130B2/ja active Active
-
2024
- 2024-05-21 AU AU2024203373A patent/AU2024203373A1/en active Pending
- 2024-06-19 US US18/747,889 patent/US20240376083A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023535236A (ja) | 2023-08-16 |
| PE20230737A1 (es) | 2023-05-03 |
| JP7756130B2 (ja) | 2025-10-17 |
| US20240376083A1 (en) | 2024-11-14 |
| WO2022046606A1 (en) | 2022-03-03 |
| DOP2023000038A (es) | 2023-03-15 |
| US20220056013A1 (en) | 2022-02-24 |
| AU2021333558A1 (en) | 2023-03-02 |
| KR20230057396A (ko) | 2023-04-28 |
| MX2023002256A (es) | 2023-03-17 |
| AU2021333558B2 (en) | 2024-02-22 |
| AU2021333558C1 (en) | 2024-06-20 |
| JP2024016014A (ja) | 2024-02-06 |
| EP4200293A1 (en) | 2023-06-28 |
| TW202530197A (zh) | 2025-08-01 |
| CA3189181A1 (en) | 2022-03-03 |
| ECSP23012981A (es) | 2023-03-31 |
| CL2023000525A1 (es) | 2023-09-15 |
| US12043613B2 (en) | 2024-07-23 |
| BR112023002575A2 (pt) | 2023-03-07 |
| CO2023001975A2 (es) | 2023-03-07 |
| AU2024203373A1 (en) | 2024-06-13 |
| TWI786777B (zh) | 2022-12-11 |
| ZA202301801B (en) | 2024-09-25 |
| TW202334117A (zh) | 2023-09-01 |
| TW202214597A (zh) | 2022-04-16 |
| JP7349046B2 (ja) | 2023-09-21 |
| CR20230113A (es) | 2023-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL300586A (en) | SARM1 inhibitors | |
| US12331033B2 (en) | Inhibitors of SARM1 | |
| JP7319395B2 (ja) | Ｓａｒｍ１の阻害剤 | |
| EP4132920B1 (en) | Indazole derivatives as inhibitors of sarm1 | |
| EP4132928B1 (en) | Condensed pyrazole derivatives as inhibitors of sarm1 | |
| JP7746384B2 (ja) | Ｓａｒｍ１のベンゾピラゾール阻害剤 | |
| JP2022547707A (ja) | Ｓａｒｍ１の阻害剤 | |
| EA048703B1 (ru) | Ингибиторы sarm1 | |
| CN116940569A (zh) | Sarm1抑制剂 |